Valeant divests Sprout back to former owners

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it will divest its Sprout Pharmaceuticals Inc. subsidiary back to Sprout's former shareholders. The deal is expected to close by year end.

In 2015, Valeant acquired Sprout for $1 billion in cash and gained Sprout's only marketed drug Addyi flibanserin (see BioCentury Extra, Aug. 20, 2015)...